Daiichi Sankyo Co., Ltd. (DSKYF)
OTC PINK OTC PINK Primary Summary
DSKYF Chart
Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 FY2025 Earnings Call July 31, 2025 4:30 AM ET Company Participants Asakura - VP of Corporate Communications Koji Ogawa - Senior Executive Officer and CFO Yuki Abe - R&D Division Head Conference Call Participants Barker - Jefferies. Hashiguchi - Daiwa Securities Muraoka - Morgan Stanley MUFG Ren - Macquarie Sakai - UBS Securities Wakao - JPMorgan Yamaguchi - Citigroup Securities Asakura Thank you very much for joining us.
Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Hiroyuki Okuzawa - Representative Director, President and CEO Koji Ogawa - Senior Executive Officer and CFO Ken Takeshita - Head of Global R&D Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Akinori Ueda - Goldman Sachs Shinichiro Muraoka - Morgan Stanley MUFG Stephen Barker - Jeffries Securities Fumiyoshi Sakai - UBS Securities Kazuaki Hashiguchi - Daiwa Securities Taito Kurose - Nikkei Newspaper Yui Hasebe - Bloomberg Kentaro Asakura Thank you for waiting. Now we would like to begin Daiichi Sankyo's Financial Results Conference on FY2024.
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Koji Ogawa - Head of Global Corporate Planning & Management, CFO Ken Takeshita - Head of Global R&D Yuki Abe - Corporate Officer and Head of the R&D Division Hiroyuki Okuzawa - Representative Director, President and COO Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Stephen Barker - Jeffries Securities Taito Kurose - Nikkei Newspaper Shinichiro Muraoka - Morgan Stanley MUFG Fumiyoshi Sakai - UBS Securities Hiroshi Wada - SMBC Nikko Securities Inc. Miki Sogi - Sanford Bernstein Kentaro Asakura Thank you very much for waiting. We will now would like to start Daiichi Sankyo's Financial Results Briefing for the Third Quarter of Fiscal Year 2024.
Daiichi Sankyo Co., Ltd. Dividends
| DSKYF In 7 months | Other | $0.27 Per Share |
| DSKYF In 1 month | Other | $0.27 Per Share |
| DSKYF 4 months ago Paid | Other | $0.2 Per Share |
| DSKYF 10 months ago Paid | Other | $0.19 Per Share |
| DSKYF 10 months ago | Other | $0.21 Per Share |
Daiichi Sankyo Co., Ltd. Earnings
| 30 Oct 2025 (In 2 months) Date | | 24.12 Cons. EPS | - EPS |
| 28 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 31 Jul 2025 Date | | 23.76 Cons. EPS | 0.32 EPS |
| 29 Jul 2025 Date | | - Cons. EPS | - EPS |
| 23 Apr 2025 Date | | - Cons. EPS | - EPS |
| DSKYF In 7 months | Other | $0.27 Per Share |
| DSKYF In 1 month | Other | $0.27 Per Share |
| DSKYF 4 months ago Paid | Other | $0.2 Per Share |
| DSKYF 10 months ago Paid | Other | $0.19 Per Share |
| DSKYF 10 months ago | Other | $0.21 Per Share |
| 30 Oct 2025 (In 2 months) Date | | 24.12 Cons. EPS | - EPS |
| 28 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 31 Jul 2025 Date | | 23.76 Cons. EPS | 0.32 EPS |
| 29 Jul 2025 Date | | - Cons. EPS | - EPS |
| 23 Apr 2025 Date | | - Cons. EPS | - EPS |
Daiichi Sankyo Co., Ltd. (DSKYF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Daiichi Sankyo Co., Ltd. ever had a stock split?
Daiichi Sankyo Co., Ltd. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Hiroyuki Okuzawa CEO | OTC PINK Exchange | JP3475350009 ISIN |
| JP Country | 18,726 Employees | 31 Mar 2026 Last Dividend | 29 Sep 2020 Last Split | - IPO Date |
Overview
Daiichi Sankyo Company, Limited is a global pharmaceutical company founded in 1899, with its headquarters in Tokyo, Japan. It operates across various regions including Japan, North America, Europe, and other international markets. The company is dedicated to the manufacture and sale of pharmaceutical products. Their portfolio includes a variety of drugs for treating cancer, iron deficiency, hypertension, cholesterol, diabetes mellitus, migraine attacks, osteoporosis, neuropathic pain, and seizures, among others. Additionally, they provide vaccines for several infectious diseases. Daiichi Sankyo has established strategic collaborations with notable entities like Merck & Co., Inc. and AstraZeneca UK Limited for the development of anti-cancer drugs.
Products and Services
Enhertu: A treatment for patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors.
Turalio: An oral small molecule targeting CSF1R, KIT, and FLT3-ITD mutation for specific cancers.
Vanflyta: A FLT3 inhibitor used in the treatment of adult patients with acute myeloid leukemia.
Injectafer: A ferric carboxymaltose injection to address iron deficiency.
Liziana and Savaysa: Anticoagulants acting as direct factor Xa inhibitors.
Antihypertensive Agents (Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, Sevikar HCT): A series of drugs designed to treat hypertension.
Nilemdo: An oral treatment that lowers cholesterol.
Nustendi: A combination tablet of bempedoic acid and ezetimibe for cholesterol reduction.
Efient: An anti-platelet agent.
Diabetes Treatments (Canalia and Tenelia): Medications for the management of type 2 diabetes mellitus.
Migraine Treatments (Emgalty and Reyvow): Drugs to treat migraine attacks.
Pralia: A treatment for osteoporosis and inhibitor of the progression of bone erosion associated with rheumatoid arthritis.
Ranmark: Addresses bone complications from bone metastasis from tumors.
Tarlige: For the treatment of neuropathic pain.
Venofer: Treats iron deficiency anemia.
Vimpat: An anti-seizure medication.
Vaccines: Providing protection against COVID-19, influenza, H5N1 influenza, measles/rubella, and mumps.
Contact Information
